XTL Biopharmaceuticals Ltd. (XTLB.TA)
ILA 4.8
(4.35%)
ILA 4.8
(4.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -765 Thousand USD | 99.91% |
| 2022 | -880 Thousand USD | 14.65% |
| 2021 | -1.03 Million USD | -8.76% |
| 2020 | -948 Thousand USD | -12.59% |
| 2019 | -842 Thousand USD | -6.18% |
| 2018 | -793 Thousand USD | 36.36% |
| 2017 | -1.24 Million USD | 51.35% |
| 2016 | -2.56 Million USD | 29.08% |
| 2015 | -3.61 Million USD | -78.59% |
| 2014 | -2.02 Million USD | 30.13% |
| 2013 | -2.89 Million USD | -22.84% |
| 2012 | -2.35 Million USD | -102.58% |
| 2011 | -1.16 Million USD | 7.4% |
| 2010 | -1.25 Million USD | -148.91% |
| 2009 | 2.56 Million USD | 126.78% |
| 2008 | -9.59 Million USD | 62.73% |
| 2007 | -25.73 Million USD | -60.38% |
| 2006 | -16.04 Million USD | -11.59% |
| 2005 | -14.38 Million USD | 14.28% |
| 2004 | -16.77 Million USD | -215.2% |
| 2003 | 14.56 Million USD | 182.22% |
| 2002 | -17.71 Million USD | -17.11% |
| 2001 | -15.12 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -175 Thousand USD | -87400.0% |
| 2023 Q2 | -163 Thousand USD | 35.06% |
| 2023 Q3 | -151 Thousand USD | 7.36% |
| 2023 Q4 | -200.00 USD | 99.87% |
| 2023 Q1 | -251 Thousand USD | -11.56% |
| 2023 FY | -765.00 USD | 99.91% |
| 2022 Q4 | -225 Thousand USD | -10.29% |
| 2022 Q3 | -204 Thousand USD | -0.99% |
| 2022 FY | -880 Thousand USD | 14.65% |
| 2022 Q2 | -202 Thousand USD | 18.88% |
| 2022 Q1 | -249 Thousand USD | 12.94% |
| 2021 Q4 | -286 Thousand USD | 35.29% |
| 2021 Q1 | -232 Thousand USD | 9.73% |
| 2021 Q2 | -535 Thousand USD | -130.6% |
| 2021 FY | -1.03 Million USD | -8.76% |
| 2021 Q3 | -442 Thousand USD | 17.38% |
| 2020 Q1 | -257 Thousand USD | -5.33% |
| 2020 FY | -948 Thousand USD | -12.59% |
| 2020 Q4 | -257 Thousand USD | -18.43% |
| 2020 Q3 | -217 Thousand USD | 54.22% |
| 2020 Q2 | -474 Thousand USD | -84.44% |
| 2019 Q3 | -199 Thousand USD | 0.5% |
| 2019 Q2 | -200 Thousand USD | -0.5% |
| 2019 Q4 | -244 Thousand USD | -22.61% |
| 2019 Q1 | -199 Thousand USD | 9.95% |
| 2019 FY | -842 Thousand USD | -6.18% |
| 2018 Q3 | -190 Thousand USD | -3.26% |
| 2018 Q2 | -184 Thousand USD | 7.07% |
| 2018 Q1 | -198 Thousand USD | 30.77% |
| 2018 Q4 | -221 Thousand USD | -16.32% |
| 2018 FY | -793 Thousand USD | 36.36% |
| 2017 FY | -1.24 Million USD | 51.35% |
| 2017 Q4 | -286 Thousand USD | -50.53% |
| 2017 Q3 | -190 Thousand USD | 57.11% |
| 2017 Q1 | -327 Thousand USD | 72.59% |
| 2017 Q2 | -443 Thousand USD | -35.47% |
| 2016 FY | -2.56 Million USD | 29.08% |
| 2016 Q2 | -466 Thousand USD | 22.59% |
| 2016 Q3 | -300 Thousand USD | 35.62% |
| 2016 Q1 | -602 Thousand USD | 74.47% |
| 2016 Q4 | -1.19 Million USD | -297.67% |
| 2015 Q2 | -481 Thousand USD | -27.93% |
| 2015 Q4 | -2.35 Million USD | -495.45% |
| 2015 FY | -3.61 Million USD | -78.59% |
| 2015 Q1 | -376 Thousand USD | -623.08% |
| 2015 Q3 | -396 Thousand USD | 17.67% |
| 2014 Q3 | -494 Thousand USD | 31.67% |
| 2014 FY | -2.02 Million USD | 30.13% |
| 2014 Q4 | -52 Thousand USD | 89.47% |
| 2014 Q1 | -753 Thousand USD | 58.17% |
| 2014 Q2 | -723 Thousand USD | 3.98% |
| 2013 FY | -2.89 Million USD | -22.84% |
| 2013 Q4 | -1.8 Million USD | -317.13% |
| 2013 Q3 | 829 Thousand USD | 182.9% |
| 2013 Q2 | -1 Million USD | -8.34% |
| 2013 Q1 | -923 Thousand USD | -51.81% |
| 2012 Q4 | -608 Thousand USD | 20.94% |
| 2012 Q1 | -401 Thousand USD | -41.7% |
| 2012 Q2 | -597 Thousand USD | -48.88% |
| 2012 Q3 | -769 Thousand USD | -28.81% |
| 2012 FY | -2.35 Million USD | -102.58% |
| 2011 Q4 | -283 Thousand USD | 9.0% |
| 2011 FY | -1.16 Million USD | 7.4% |
| 2011 Q3 | -311 Thousand USD | -5.07% |
| 2011 Q2 | -296 Thousand USD | 11.38% |
| 2011 Q1 | -334 Thousand USD | -8.44% |
| 2010 Q4 | -308 Thousand USD | -4.05% |
| 2010 FY | -1.25 Million USD | -148.91% |
| 2010 Q2 | -317 Thousand USD | 5.37% |
| 2010 Q1 | -335 Thousand USD | -9.84% |
| 2010 Q3 | -296 Thousand USD | 6.62% |
| 2009 Q3 | 14 Thousand USD | -98.85% |
| 2009 Q2 | 1.21 Million USD | -26.31% |
| 2009 FY | 2.56 Million USD | 126.78% |
| 2009 Q1 | 1.64 Million USD | 132.16% |
| 2009 Q4 | -305 Thousand USD | -2278.57% |
| 2008 Q1 | 1.97 Million USD | 107.39% |
| 2008 Q2 | -3.63 Million USD | -284.26% |
| 2008 FY | -9.59 Million USD | 62.73% |
| 2008 Q3 | -1.35 Million USD | 62.56% |
| 2008 Q4 | 709 Thousand USD | 152.17% |
| 2007 Q2 | -7.6 Million USD | -6772.81% |
| 2007 Q3 | 226 Thousand USD | 102.97% |
| 2007 Q4 | -26.64 Million USD | -11888.5% |
| 2007 FY | -25.73 Million USD | -60.38% |
| 2007 Q1 | 114 Thousand USD | 100.7% |
| 2006 FY | -16.04 Million USD | -11.59% |
| 2006 Q4 | -16.38 Million USD | -14474.56% |
| 2006 Q2 | -3.75 Million USD | -3392.98% |
| 2006 Q1 | 114 Thousand USD | 100.74% |
| 2006 Q3 | 114 Thousand USD | 103.04% |
| 2005 Q1 | 1.3 Million USD | 106.73% |
| 2005 Q2 | -2.54 Million USD | -294.79% |
| 2005 Q3 | 295 Thousand USD | 111.61% |
| 2005 Q4 | -15.5 Million USD | -5354.24% |
| 2005 FY | -14.38 Million USD | 14.28% |
| 2004 Q3 | 864 Thousand USD | 117.1% |
| 2004 Q4 | -19.36 Million USD | -2341.67% |
| 2004 Q2 | -5.05 Million USD | -684.95% |
| 2004 Q1 | 864 Thousand USD | 0.0% |
| 2004 FY | -16.77 Million USD | -215.2% |
| 2003 FY | 14.56 Million USD | 182.22% |
| 2002 FY | -17.71 Million USD | -17.11% |
| 2001 FY | -15.12 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Matricelf Ltd | -12.59 Million ILA | 93.927% |